Biomarker Panel for Inflammation-Related Platelet Activation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting platelet activation linked to inflammation are not efficient, as they often require measuring multiple molecules and lack specificity, making it difficult to accurately diagnose and monitor inflammatory diseases.
Innovation Solution
A panel of seven biomarkers (AKT, PKC, CD62P, CD63, RANTES, TSLP, and CD40 ligand) is identified and measured to detect platelet activation linked to inflammation, allowing for specific detection and monitoring of platelet activation in inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple molecules are measured to detect platelet activation, then detection reliability is improved, but device complexity and measurement time increase
Solution Approach 1:
The detection method is segmented into two distinct parts: (1) measurement of platelet activation markers (P-selectin, CD63, CD40L) to assess activation state, and (2) measurement of inflammation markers (CRP, IL-6, TNF-alpha) to assess inflammatory context. This segmentation allows the system to differentiate between activation due to inflammation versus other causes, improving reliability while maintaining manageable complexity through modular measurement approaches.
Solution Approach 2:
The detection system is designed with multi-functionality to simultaneously measure multiple types of markers (platelet activation markers and inflammation markers) using a unified approach. This universal detection capability improves reliability by providing comprehensive assessment while avoiding the need for separate specialized systems for each marker type.
2Reliability
If multiple molecules are measured to detect platelet activation, then detection reliability is improved, but measurement time increases
Solution Approach 1:
The measurement process is segmented into targeted panels that can be executed efficiently: platelet activation marker measurement and inflammation marker measurement. This segmentation enables parallel processing or prioritized measurement sequences, reducing total measurement time while maintaining comprehensive assessment for reliable detection.
3Measurement precision
If a panel of seven biomarkers is measured, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The seven-biomarker panel is segmented into functionally related groups: platelet activation markers (P-selectin/CD62P, CD63, CD40L) and inflammation markers (CRP, IL-6, TNF-alpha). This segmentation allows the detection system to process markers in organized modules, improving measurement precision through focused assessment while managing device complexity through structured measurement protocols.
Solution Approach 2:
The detection system achieves universal capability to measure all seven biomarkers through a unified platform that can handle both platelet activation markers and inflammation markers. This multi-functional approach improves measurement precision by providing comprehensive biomarker assessment while avoiding the need for multiple separate specialized devices.
4Measurement precision
If a panel of seven biomarkers is measured, then measurement precision is improved, but loss of time increases
Solution Approach 1:
The seven-biomarker measurement is segmented into efficient measurement sequences or parallel assays, allowing precision improvement through comprehensive assessment while minimizing time loss through optimized measurement workflows.
Solution Approach 2:
The system implements measurement of a focused panel of seven key biomarkers rather than exhaustive measurement of all possible markers. This partial action approach achieves sufficient measurement precision for clinical decision-making while significantly reducing measurement time compared to comprehensive proteomic analysis.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for detecting inflammation-related platelet activation, comprising measuring the quantity, concentration and/or proportion of seven specific biomarkers representative of 47 intra-platelet, soluble and membrane molecules, in a biological sample. Said panel of seven biomarkers is particularly useful for implementing a method for diagnosing inflammation-related platelet activation in an individual, a method for monitoring the effectiveness of a curative or preventive treatment of an inflammatory disease in an individual and/or a method for monitoring the development of an inflammatory disease associated with inflammation-related platelet activation in an individual. The present invention also relates to a kit for detecting inflammation-related platelet activation, as well as the use thereof.